Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Appointed CFO
Quarterly results
Auditor change
Eledon Pharmaceuticals, Inc. (NVUS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results Ninth patient dosed in ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation; updated clinical data expected in the fourth quarter Raised up to $185 million, including $35 million upfront, from leading investors Successfully completed a non-human primate study for subcutaneous tegoprubart formulation"
05/11/2023 8-K Quarterly results
Docs: "Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results Reported open-label data from ongoing Phase 1b trial of tegoprubart in kidney transplantation demonstrating mean eGFRs from 3 participants above 70 mL/min/1.73m2 at measured timepoints Completed financing of up to $185 million, with $35 million upfront, to fund the Company through the Phase 2 BESTOW kidney transplant trial, subject to achieving specific milestones Conference call today at 4:30 p.m. ET"
11/14/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/24/2022 8-K Quarterly results
Docs: "Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022"
11/12/2021 8-K Quarterly results
Docs: "Eledon Pharmaceuticals Reports Third Quarter 2021 Operating and Financial Results Nearing full enrollment in ALS Phase 2 Study; topline data expected 1H 2022"
08/12/2021 8-K Quarterly results
05/15/2020 8-K Quarterly results
Docs: "Novus Therapeutics Reports First Quarter 2020 Financial Results"
03/17/2020 8-K Quarterly results
Docs: "Novus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results Data from the fully enrolled phase 2a efficacy study in infants and children with acute otitis media to be announced by early June 2020"
11/13/2019 8-K Quarterly results
08/13/2019 8-K Quarterly results
Docs: "Novus Therapeutics Reports Second Quarter 2019 Financial Results"
05/14/2019 8-K Quarterly results
Docs: "Novus Therapeutics Reports First Quarter 2019 Financial Results"
03/28/2019 8-K Quarterly results
Docs: "Novus Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Clinical Updates"
11/13/2018 8-K Quarterly results
Docs: "Novus Therapeutics Reports Third Quarter 2018 Financial Results"
08/07/2018 8-K Quarterly results
Docs: "Novus Therapeutics Reports Second Quarter 2018 Financial Results"
03/30/2018 8-K Quarterly results
Docs: "Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update"
11/08/2017 8-K Quarterly results
Docs: "Novus Therapeutics Reports Third Quarter 2017 Results"
08/10/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 August 9, 2017 Date of Report Novus Therapeutics, Inc. Delaware 001-36620 20-1000967 19900 MacArthur Blvd., Suite 550 Irvine, California 92612 238-8090 Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exch...",
"Novus Therapeutics Reports Second Quarter 2017 Results IRVINE, Calif., August 9, 2017 /PRNewswire/ — Novus Therapeutics, Inc. , a development stage specialty pharmaceutical company focused on the development of products for disorders of the ear, nose, and throat , today reported results for the second quarter 2017. For the three months ended June 30, 2017, Novus reported a net loss of $6.7 million or $1.32 per share. This compares to a net loss of $1.0 million or $2.25 per share for the same period in the prior year. For the six months ended June 30, 2017, Novus reported a net loss of $8.0 million or $2.51 per share. This compares to a net loss of $2.1 million or $4.68 per share for the same period in the prior year. Novus ended the second quarter of 2017 with $22.5 million in cash and cas..."
11/10/2014 8-K Quarterly results
Docs: "Tokai Pharmaceuticals Reports Third Quarter 2014 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy